The United Laboratories International (HKG:3933) unit Zhuhai United Laboratories obtained approval for the clinical trial of TUL108 for Injection from China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.
The drug is intended to treat infections caused by Gram-negative or Gram-positive bacteria, including complicated urinary tract infections, complicated intra-abdominal infections, pulmonary infections, and bloodstream infections.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments